NASDAQ$PAHC
Phibro Animal Health Corporation · Q4 2025 earnings
Q4 2025 earnings · · After market close · Investor relations
Briefing
Phibro Animal Health Corporation reported strong Q4 2025 results with 39% revenue growth driven by the Zoetis MFA acquisition and portfolio demand.
Net sales reached $378.7 million, up 39% year-over-year, with net income of $17.2 million and adjusted EBITDA of $50.0 million. Animal Health segment sales grew 53% to $292.5 million, fueled by MFAs and other products. The company provided FY2026 guidance reflecting continued growth across segments.
- Q4 net sales increased 39% to $378.7 million, led by $101.0 million growth in Animal Health.
- Adjusted EBITDA rose 49% to $50.0 million; adjusted diluted EPS increased 39% to $0.57.
- Full-year net sales grew 27% to $1,296.2 million with adjusted EBITDA up 65% to $183.7 million.
- FY2026 guidance projects net sales of $1.43B-$1.48B and adjusted EBITDA of $225M-$235M.
Headline financials
Revenue & EPS history
Phibro · Revenue · Quarterly
$379M
Revenue by segment
Phibro · $671M total across 6 segments · Q4 2025
- Animal Health$293M—43.6%
- MFAs and other$207M—30.8%
- Mineral Nutrition$64.2M—9.6%
- Nutritional specialties$47.4M—7.1%
- Vaccines$38.6M—5.8%
- Performance Products$22.1M—3.3%
Forward guidance
FY2026 guidance includes net sales of $1.43B to $1.48B and adjusted EBITDA of $225M to $235M, reflecting continued growth across Animal Health, Mineral Nutrition, and Performance Products.
Tailwinds
- 12% net sales growth expected
- 25% adjusted EBITDA growth projected
- Momentum across all segments
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2025
+0.3%
Avg return
Earnings day
+1.3%
Avg return
5 days after
-0.9%
Avg return
30 days after
57%
30 / 53 earnings
Positive
+22.0%
Q2 2026
Best reaction
-31.5%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | -26.1% | -37.5% | -44.6% | |
| Q2 2026 | +22.0% | +26.2% | +16.9% | |
| Q1 2026 | +4.7% | +10.2% | -4.8% | |
| Q4 2025 | +19.4% | +13.9% | +20.5% | |
| Q3 2025 | +14.7% | +26.9% | +24.2% | |
| Q2 2025 | +9.9% | +16.8% | +5.7% | |
| Q1 2025 | +2.8% | +11.8% | +1.6% | |
| Q4 2024 | +1.9% | -0.3% | +4.8% | |
| Q3 2024 | +5.5% | +8.0% | +2.3% | |
| Q2 2024 | +5.9% | +12.5% | +19.1% | |
| Q1 2024 | -18.9% | -19.3% | -8.4% | |
| Q4 2023 | -5.8% | -2.0% | -13.8% | |
| Q3 2023 | -8.4% | -8.0% | -12.0% | |
| Q2 2023 | -0.9% | -1.3% | -4.7% | |
| Q1 2023 | -5.5% | -8.0% | -14.2% | |
| Q4 2022 | -4.8% | -7.4% | -24.4% | |
| Q3 2022 | -4.0% | -2.9% | -0.5% | |
| Q2 2022 | +5.7% | +13.7% | +6.0% | |
| Q1 2022 | -0.8% | -0.3% | -10.1% | |
| Q4 2021 | -5.0% | -1.0% | -10.2% | |
| Q3 2021 | +8.1% | +3.9% | +14.7% | |
| Q2 2021 | +7.3% | +7.9% | +7.5% | |
| Q1 2021 | +4.5% | +8.1% | +10.0% | |
| Q4 2020 | +0.9% | +4.6% | -13.0% | |
| Q3 2020 | -4.6% | -4.8% | +15.7% | |
| Q2 2020 | +16.9% | +14.0% | +12.5% | |
| Q1 2020 | -8.1% | -4.8% | -0.0% | |
| Q4 2019 | -31.5% | -35.0% | -32.5% | |
| Q3 2019 | -19.7% | -17.2% | -17.0% | |
| Q2 2019 | -6.4% | -10.4% | -11.8% | |
| Q1 2019 | -8.7% | -12.5% | -22.1% | |
| Q4 2018 | -3.0% | -7.0% | -15.3% | |
| Q3 2018 | +4.2% | +3.2% | +9.7% | |
| Q2 2018 | +6.8% | +4.4% | +16.0% | |
| Q1 2018 | -4.9% | -8.2% | -12.9% | |
| Q4 2017 | -5.1% | -2.4% | -0.9% | |
| Q3 2017 | +6.0% | +10.9% | +18.4% | |
| Q2 2017 | +7.0% | +12.1% | +0.2% | |
| Q1 2017 | +11.3% | +8.9% | +3.4% | |
| Q4 2016 | +15.4% | +24.9% | +28.9% | |
| Q3 2016 | -10.3% | — | — | |
| Q2 2016 | -18.2% | — | — | |
| Q1 2016 | -3.4% | — | — | |
| Q4 2015 | -5.3% | — | — | |
| Q3 2015 | +7.9% | — | — | |
| Q2 2015 | +6.5% | — | — | |
| Q1 2014 | +5.5% | — | — | |
| Q1 2015 | +7.4% | — | — | |
| Q2 2014 | +0.3% | — | — | |
| Q4 2014 | +12.6% | — | — | |
| Q4 2013 | +1.0% | — | — | |
| Q3 2013 | +1.0% | — | — | |
| Q3 2014 | +1.0% | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro